About

Ayush Kumar is a Research Assistant Professor in the Department of Computer Science at Stony Brook University, NY, USA, and a Postdoctoral Research Fellow at the Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, USA. He received his Ph.D. in Computer Science from Stony Brook University in 2020 under the supervision of Professor Klaus Mueller. His research focuses on helping users make sense of big multi-dimensional data by integrating data visualization, machine learning, and computer vision techniques. He applies these methods in assistive technology for individuals with visual impairments, utilizing eye-tracking and vision science. In recognition of his work, Ayush was awarded the ICTCCP Research Excellence Award in 2018 and received a Ph.D. Fellowship from SFB-TRR 161 (DFG) in 2016 for a project on adaptive self-consistent visualization.

Research topics

• Medicine
• Pathology
• Internal medicine
• Microbiology
• Dentistry
• Biology
• Physical therapy
• Nursing
• Dermatology
• Radiology
• Medical physics
• Intensive care medicine

Selected publications

• Endoscopic vacuum therapy for the management of nonvariceal upper gastrointestinal bleeding: a valuable resource for the endoscopist’s toolbox

  Endoscopy · 2025-02-21 · 2 citations

  article

  Background: Endoscopic vacuum therapy (EVT) is a well-established method for managing gastrointestinal perforations. During the COVID pandemic, case reports demonstrated the effective use of EVT in controlling COVID-related diffuse duodenal bleeding. Owing to its unique mechanism of action, this approach may also be effective for other types of nonvariceal upper gastrointestinal bleeding (NVUGIB). This study aimed to assess EVT in the treatment of NVUGIB. Methods: This retrospective analysis of a prospectively collected database included patients who underwent EVT for the treatment of NVUGIB. The primary outcome was clinical success. Secondary outcomes included technical success and safety. Subgroup analysis comparing the outcomes for patients with and without COVID was conducted. Results: 19 patients underwent EVT for NVUGIB, with 57.9% having failed other therapies. Technical success occurred in all patients, and clinical success was achieved in 89.5%. There was no difference in the clinical success rates between patients with or without COVID (88% versus 91%, respectively). No procedure-related adverse events occurred. Conclusion: EVT appears to be safe and effective in the management of NVUGIB. This approach could be particularly useful in refractory or diffuse bleeding. Larger studies are warranted to validate these findings.

  PublisherDOI

• MANAGEMENT OF POST SURGICAL BILIARY STRICTURES IN A TERTIARY LEVEL TEACHING HOSPITAL OF GUJARAT,A 09 YEARS EXPERIENCE OF A SINGLE GASTROSURGICAL TEAM

  International Journal of Advanced Research · 2025-10-31

  articleOpen access

  Introduction: Bile duct injury (BDI) following cholecystectomy continues to be a serious iatrogenic complication that significantly affects patients quality of life and results in high healthcare costs. Although the incidence of BDI during laparoscopic cholecystectomy has marginally increased (.4% to .6%) as compared to 1 to .2% during open cholecystectomy {18},the overall number of cases remains substantial due to t he high frequency of cholecystectomy procedures{1,13}. If bile duct injury (BDI) is not properly managed, it can lead to biliary stricture, which may result in serious complications such as recurrent strictures, cholangitis, or even liver function impairment leading to even cirrhosis. Open Roux-en-Y hepaticojejunostomy{RY HJ}, when performed with precise surgical technique, continues to be the gold standard treatment, providing excellent long-term outcomes for most patients. Methodology:This is a descriptive observational study with retrospecti ve data analysis and prospective data collection with follow up which includes 60 patients, aged between 16 and 65 years, from a single gastrosurgery unit at SMT NHL Municipal Medical College in Ahmeda bad, conducted over a 09-year period August 2015 and September 2024. Patients who underwent surgical management for definitive treatment of biliary injuries in the form of Roux en Y hepaticojejunosto my (R-en-Y HJ), were included in the study. The study analysed demographic data, factors affecting surgical complications, long-term outcomes, and follow-up results.

  PublisherDOI

• Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study

  International Journal of COPD · 2024-08-01 · 8 citations

  articleOpen access

  Purpose: This study evaluated the long-term safety of roflumilast in patients with chronic obstructive pulmonary disease or chronic bronchitis using electronic healthcare databases from Germany, Norway, Sweden, and the United States (US). Patients and Methods: The study population consisted of patients aged ≥40 years who had been exposed to roflumilast and a matched cohort unexposed to roflumilast. The matching was based on sex, age, calendar year of cohort entry date (2010-2011, 2012, or 2013), and a propensity score that included variables such as demographics, markers of chronic obstructive pulmonary disease (COPD) severity and morbidity, and comorbidities. In comparison to the unexposed matched cohort (never use), three exposure definitions were used for the exposed matched cohort: ever use, use status (current, recent, past use), and cumulative duration of use. The main outcome was 5-year all-cause mortality. Cox regression models were used to estimate crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CI). Results: 112,541 unexposed and 23,239 exposed patients across countries were included. Some variables remained unbalanced after matching, indicating higher COPD disease severity among the exposed patients. Adjusted HRs of 5-year all-cause mortality for "ever use" of roflumilast, compared to "never use", were 1.12 (95% CI, 1.08-1.17) in Germany, 1.00 (95% CI, 0.92-1.08) in Norway, 0.98 (95% CI, 0.92-1.04) in Sweden, and 1.16 (95% CI, 1.12-1.20) in the US. Compared to never users, there was a decrease in 5-year mortality risk observed among "current users" in Germany (HR: 0.93, 95% CI: 0.88-0.98), Norway (HR: 0.77, 95% CI: 0.67-0.87), and Sweden (HR: 0.80, 95% CI: 0.73-0.88). Conclusion: There was no observed increase in 5-year mortality risk with the use of roflumilast in Sweden or Norway. A small increase in 5-year mortality risk was observed in Germany and the US in the ever versus never comparison, likely due to residual confounding by indication.

  PublisherOA PDFDOI

• A bio-nano-engineered platform fabricated from cerium oxide-carbon nanoparticles stabilized with chitosan for label-free sensing of a lung cancer biomarker

  Analytical Methods · 2024-11-22 · 7 citations

  article

  This study reports the synthesis of CeO 2 and its nanocomposite with carbon nanoparticles stabilized by the chitosan polymer matrix for the early detection of a cancer biomarker.

  PublisherDOI

• LONG TERM OUTCOMES OF SALVAGE POEM AFTER FAILED HELLER IN A LARGE US COHORT. COMPARISON OF OUTCOMES TO THOSE OF POEM IN TREATMENT NAIVE PATIENTS

  Gastrointestinal Endoscopy · 2024-06-01

  article
  PublisherDOI

• Cholesterol Absorption Inhibition by Some Nutraceuticals

  Recent Advances in Food Nutrition & Agriculture · 2024-03-05

  review

  Hyperlipidemia, characterized by elevated levels of lipids in the blood, represents a major risk factor for cardiovascular diseases, a leading cause of morbidity and mortality worldwide. Conventional pharmacological interventions have been effective in managing hyperlipidemia, but concerns about side effects and long-term use have prompted interest in alternative approaches, particularly the use of nutraceuticals. This comprehensive review aims to summarize and critically evaluate the current body of knowledge surrounding the role of nutraceuticals in the management of hyperlipidemia. We provide an overview of the different classes of nutraceuticals, including plant sterols, omega-3 fatty acids, soluble fiber, antioxidants, and various herbal extracts, which have been investigated for their lipid-lowering properties. The mechanisms of action of these nutraceuticals are discussed, highlighting their ability to modulate lipid metabolism, reduce oxidative stress, and promote cardiovascular health. Furthermore, we review the results of clinical trials and epidemiological studies that have assessed the efficacy of nutraceutical interventions in lowering cholesterol levels, improving lipid profiles, and reducing the risk of cardiovascular events. In addition to their lipid-lowering effects, we examine the safety profile, dosage recommendations, and potential interactions of nutraceuticals with conventional lipid-lowering medications. We also address the importance of patient adherence to dietary and lifestyle modifications in conjunction with nutraceutical supplementation. While nutraceuticals offer a promising avenue for managing hyperlipidemia, we emphasize the need for further research to establish evidence-based guidelines for their use in clinical practice. Challenges related to standardization, quality control, and regulatory considerations are also discussed. In conclusion, this comprehensive review provides valuable insights into the potential of nutraceuticals as adjunctive or alternative therapies for managing hyperlipidemia. While further research is needed, the accumulating evidence suggests that nutraceuticals can play a valuable role in promoting cardiovascular health and reducing the burden of hyperlipidemia-related diseases.

  PublisherDOI

• Nanotechnology Integrated Innovative Drug Delivery and Therapy for Cancer

  Current Pharmaceutical Biotechnology · 2024-05-06 · 5 citations

  reviewSenior author

  Cancer remains a significant global health challenge, necessitating innovative approaches to enhance the efficacy and specificity of therapeutic interventions while minimizing adverse effects on healthy tissues. Nanotechnology has emerged as a promising avenue in cancer treatment, offering novel strategies for targeted drug delivery. Nanoparticles, liposomes, and polymer-based systems have played pivotal roles in revolutionizing cancer therapy. Nanotechnology possesses unique physicochemical properties, enabling efficient encapsulation of therapeutic agents and controlled and prolonged release at tumour sites. Advancement in formulations using nanotechnology has made it possible to make multifunctional systems that respond to the microenvironment of a tumour by releasing payloads in response to changes in pH, temperature, or enzymes. Stimuli-responsive polymers can release drugs in response to external cues, enabling site-specific drug release and minimizing systemic exposure. This review explores recent studies and preclinical trials that show how nanoparticles, liposomes, and polymerbased systems could be used to treat cancer, discussing challenges such as scalability, regulatory approval, and potential toxicity concerns along with patents published recently.

  PublisherDOI

• POEM IN TYPE 3 ACHALASIA. IS A LONG MYOTOMY NECESSARY?

  Gastrointestinal Endoscopy · 2024-06-01

  article
  PublisherDOI

• Study of Serum Albumin as a Prognostic Marker in Critically ILL Patients

  Indian Journal of Public Health Research & Development · 2022-12-16 · 1 citations

  articleOpen access

  ntroduction: Serum albumin is an important parameter in the assessment of the nutritional status of both acute and chronically ill patients(1), Low albumin levels have been associated with morbidity and mortality in critically ill patients. It is thus, important to identify the patients at the time of admission who are likely to have a poor outcome, so that such patients can be managed aggressively.AIM: Study Of Serum Albumin As a Prognostic Marker in Critically ill patients.Materials and Methods: After approval from the Institutional Ethical committee all patients were selected as per inclusion and exclusion criteria. The patients, who are critically ill was selected from MICU and Serum albumin level was measured by BECKMAN COULTER ANALYZER. The statistical analysis was performed by statistical software SPSS version 21.0.Result: The present cross- sectional study was conducted in the department of medicine, among 100 critically ill Patients The results show that there is a steady fall in serum albumin in both groups. However, the fall in nonsurvivors was more steep than survivors. When mean albumin was compared statistically at different intervals, it was found to be statistically significant.Conclusion: Serum albumin is a cheap and cost effective and is routinely measured in all critically ill patients. Thus serum albumin serves as a powerful prognostic tool for critically ill patients.

  PublisherOA PDFDOI

• A short review on osmf: oral sub mucous fibrosis

  Open access jounrals · 2021-04-20

  review

  A short review on osmf: oral sub mucous fibrosis - Oral submucous fibrosis (OSMF) is a premalignant condition caused by betel

  Publisher

Frequent coauthors

• Bhawna Halwan

  97 shared

• Everson Luiz de Almeida Artifon

  Universidade de São Paulo

  59 shared

• Paulo Sakai

  42 shared

• Vivek Mittal

  Cornell University

  40 shared

• Juan Carlos Bucobo

  North Shore University Hospital

  39 shared

• Michael G. Harris

  36 shared

• Robert D. Shaw

  Dartmouth–Hitchcock Medical Center

  36 shared

• Kai Matthes

  36 shared

Awards & honors

• ICTCCP Research Excellence Award (2018)
• PhD Fellowship of SFB-TRR 161 (DFG) (2016)